6 Amazing Stocks Ready to Skyrocket This June – Grab Them Before They Take Off!

Last week’s volatility convinced many that Wednesday’s high-impact key reversal day (KRD) down was the “kiss of death.” But the reversal lacked follow-through, and that failure enhances the probability of further gains later this year. This week could be crucial in determining whether institutional investors go bargain hunting or head for the exits. My guess was that bargain hunters would dominate the holiday-shortened week, and so far, that has been the case.

But I wouldn’t expect too many new stock market highs in the summer months because it appears that the Fed has concluded that the economy has performed well enough for them to ease back slightly on further stimulus at some time in the near future.

In a somewhat overbought market, it is important to concentrate on stocks that offer unusual value. Thus, this month’s list includes stocks that, in addition to potential growth opportunities, provide dividends or special features that could enhance their value.

This perspective is not just contrary to the mainstream narrative of fear; it’s exhilarating. It suggests that while the masses fret, strategic investors like our readers can find incredible opportunities. This is especially relevant now as the summer months kick in, historically a period where the market can surprise on the upside.

Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace 

Advanced Energy Industries (NASDAQ: AEIS)

Investment Thesis

Advanced Energy Industries (NASDAQ: AEIS) provides power conversion products that transform power into various usable forms. Its products are used by semiconductor, solar panel, and similar thin-film manufacturers, such as flat panel display and data storage. S&P estimates earnings of $1.01 in 2013, $1.60 in 2014, and $1.82 in 2015.

The company’s growth trajectory is solid, with earnings expected to rise, positioning AEIS as a strong growth opportunity in sectors that are fundamentally essential to modern technology infrastructures.

Technical Analysis

The technical indicators are equally promising. AEIS recently broke free from a triple-top pattern in December, running from $15 to a high of $20 by early March. It has since been consolidating in a deep “V” formation. Accumulation has been steady, and a break above $20 could provide a target of $24. For investors, this is a high-potential growth opportunity worth watching closely.

Analyst Ratings Overview

Consensus Rating	Average Price Target	Current Price	Potential Gain	Number of Ratings
OUTPERFORM	$126.50	$108.76	16.20%	9

Summary of Analyst Outlook

Analysts’ ratings for Advanced Energy Industries (AEIS) are generally positive. The consensus rating is OUTPERFORM, indicating a positive long-term growth outlook. The average price target of $126.50 suggests a potential gain of 16.20% from the current price of $108.76. This is based on the consensus of several analysts, including Citigroup, Raymond James, and others, who have provided 12-month price targets ranging from $90.00 to $1,500.00. The stock’s performance has been noted as outperforming its sector, with a mix of buy, hold, and sell ratings.

Bank of Montreal (NYSE: BMO)

Investment Thesis

Bank of Montreal (NYSE: BMO) is the fourth-largest bank in Canada and eighth largest in North America. Although earnings for fiscal year (FY) 2013, ending in October, are estimated to be flat at $6.08, FY 2014 earnings are expected to increase to $6.42, and analysts’ median price target is $67. The stock has a dividend yield of 4.8%.

BMO combines growth potential with income generation, making it an attractive proposition for income-focused investors.

Technical Analysis

Trading near its major bullish support line and flashing a recent MACD buy signal, BMO exhibits strong technical credentials. The stock has retreated to its major bullish support line at $60 following a channel of retreating prices that began in January. However, it has held at its 200-day moving average. With a price target of $68, this represents an annual return potential exceeding 15%, ensuring that BMO offers a balanced risk-return profile with reliable dividends.

Analyst Ratings Overview

Metric	Value
Consensus Rating	Moderate Buy
Average Price Target	C$130.92
Current Price	C$114.91
Potential Gain	+14.01%
Number of Ratings	24

Summary of Analyst Outlook

Analysts are moderately optimistic about Bank of Montreal (BMO), with a consensus rating of Moderate Buy. The average price target set by analysts is C$130.92, indicating a potential increase of 14.01% from the current price of C$114.91. This moderate buying consensus suggests that while analysts are generally bullish on the stock, they do not perceive it as overwhelmingly overvalued or undervalued. The historical context and future projections for the bank, including earnings and sales estimates, suggest that analysts believe BMO can perform well within the context of its industry.

Sources:

1. Bank of Montreal Analyst Research – Nasdaq

2. Bank of Montreal (BMO) Stock Forecast & Price Target – Tipranks

3. BMO Financial Forecast – Tipranks

4. Bank of Montreal Analyst Estimates & Rating – WSJ

5. BMO.TO Stock Price & Charts – YCharts

Federal Realty Investment Trust (NYSE: FRT)

Investment Thesis

Federal Realty Investment Trust (NYSE: FRT) is a seasoned player in the REIT space, managing premium retail properties. Earnings have increased at a steady pace. The company earned $3.90 in 2010, $4.02 in 2011, $4.31 in 2012, and is expected to earn $4.59 in 2013 and $4.78 in 2014. Its consistent earnings growth highlights its operational efficiency and ability to generate returns even in fluctuating economic climates.

Technical Analysis

Following a pullback from a triple-top at $118, FRT has now generated a buy signal just above its breakout level at $110 on May 24 using a Collins-Bollinger Reversal (CBR) buy signal. This positions it with a 12-month target of $128, promising a potential total return of over 16%. For investors looking for stability in a high-quality real estate portfolio, FRT offers a compelling option.

Analyst Ratings Overview

Consensus Rating	Average Price Target	Current Price	Potential Gain	Number of Ratings
Outperform	$114.31	$100.44	13.81%	9

Summary of Analyst Outlook

Based on the provided data, analysts are generally positive about Federal Realty Investment Trust (FRT). The stock has an average price target of $114.31, indicating a potential gain of 13.81% from the current price of $100.44. Additionally, the number of buy ratings outweighs the sell and hold ratings, suggesting a strong market consensus for the stock’s performance.

Sources:

1. Nasdaq Analyst Research

2. Yahoo Finance

3. TipRanks

4. TechCrunch

5. Investing.com

Gilead Sciences (NASDAQ: GILD)

Investment Thesis

On Nov. 19, with Gilead Sciences (NASDAQ: GILD) near $37.50, I said, “This large-cap biotech is well-positioned to gain market share.” And the stock gapped up to a new high resulting from a positive study on its Hepatitis C treatment.

Gilead then suffered two setbacks in late April, when the FDA declined to approve two HIV candidate drugs. And so, on May 1, I suggested that those who bought the stock in November may want to take profits. But recently, the European Commission approved Gilead’s single-tablet regimen for the treatment of HIV-1 and the stock resumed its upward trend.

The stock is up 50% from our initial buy recommendation, and original buyers who did not take the suggestion to sell at just over $50 would be wise to hold the stock for further developments on the success of the new HIV tablet. Current holders of the stock could protect their gains by writing options. The trading target of $65 is the same as the median target of fundamental analysts. This reinforces GILD’s growth potential and resilience, making it a strong contender for investors seeking opportunities in the biotech sphere.

Analyst Ratings Overview

Info	Value
Consensus Rating	2.20
Average Price Target	$77.82
Current Price	–
Potential Gain	13.42%
Number of Ratings	63

Summary of Analyst Outlook

Analysts are optimistic about Gilead Sciences (GILD), with an average brokerage recommendation (ABR) of 2.20 out of 5, indicating a neutral consensus rating. The average price target for the stock over the next 12 months is $77.82, which implies a potential gain of 13.42%. This assessment is supported by the fact that GILD has consistently outperformed its overall industry’s sales estimates in the past year, although it has underperformed on earnings estimates.

Sources:

1. Zacks Investment Research

2. The Wall Street Journal (WSJ)

3. Nasdaq Analyst Research

4. TipRanks

5. Yahoo Finance

Omnicom Group (NYSE: OMC)

Investment Thesis

Omnicom Group (NYSE: OMC) is the owner of DDB, BBDO and TBWA global advertising agency networks, as well as over 100 marketing firms. The company is considered to be the bellwether of the international advertising business with global assets that are diversified across many industries. Following a deep “V” consolidation from September 12 to February 2013, the stock broke a double-top and ran from $55 to $58. It then developed a bull channel, breaking from its top in early May.

Technical Analysis

The last bar on the chart shows a CBR buy signal on very high volume. This is a powerful indication that prices are headed higher. Buy OMC at the market price with a trading objective of $73. This suggests significant upside potential for investors looking to tap into growth within the advertising industry.

Analyst Ratings Overview

Consensus Rating	Average Price Target	Current Price	Potential Gain	Number of Ratings
Moderate Buy	$105.56	$88.69	16.48%	10

Summary of Analyst Outlook

• Consensus Rating: The analysts have a Moderate Buy consensus rating for Omnicom Group, indicating that the majority of the analysts recommend buying the stock.
• Average Price Target: The average price target is $105.56, representing a potential increase of 16.48% from the current price of $88.69.
• Number of Ratings: The data is based on the ratings of 10 Wall Street analysts over the past 3 months.

Sources:

1. Tipranks: Provides detailed analyst forecasts and ratings for Omnicom Group Inc. (OMC).

2. Nasdaq: Offers analyst research and ratings consensus for Omnicom Group Inc. Common Stock (OMC).

3. Yahoo Finance: Offers analyst estimates, including earnings and revenue forecasts for Omnicom Group Inc. (OMC).

Pfizer (NYSE: PFE)

Investment Thesis

Pfizer (NYSE: PFE) is the world’s largest pharmaceutical company, producing a wide range of drugs. In October 2009, it acquired Wyeth. Recently, Pfizer announced plans to spin off its majority interest in animal-health company Zoetis (NYSE: ZTS) to current stockholders at $100 of PFE for $107.52 of ZTS shares, subject to SEC and stockholder approval.

This is viewed as a positive step that will allow the company to focus on its core business. The blue-chip has had a long history of earnings gains and dividend increases. The current dividend yield is 3.3%.

Technical Analysis

Pfizer’s bullish channel and strong support signals forecast a 12-month target of $35. The stock has been in a bull market since January 2012. The current bull channel’s resistance line was broken in April on high volume but after several weeks, retreated back to its normal rate of advance. Support was recently enhanced by a CBR buy signal at $28.50 and a new MACD buy signal. This reflects a potential return of 24%, reinforcing PFE’s standing as a blue-chip company that provides stability, growth, and income.

Analyst Ratings Overview

Consensus Rating	Average Price Target	Current Price	Potential Gain	Number of Ratings
Hold	$33.50	$27.93	19.48%	15

Summary of Analyst Outlook

The consensus rating among analysts for Pfizer Inc. (PFE) stock is Hold, indicating neutral expectations for the stock’s performance. The average price target suggests that the stock could rise by 19.48% to $33.50 from the